Summary Infusional 5-fluorouracil in advanced breast cancer has been associated with improved clinical response rates when compared with conventional bolus therapy. As a first line of chemotherapy in proven metastatic breast carcinoma, 258 women were randomly assigned to receive FAC consisting of 5-fluorouracil (F) 600 mg m-2 intravenously (i.v.) over 1 h on days 1, 2 and 3, doxorubicin (A) 50 were nausea and vomiting (P < 0.01). We conclude that the two regimens appeared equally effective but have different toxicities.
The aim of conventional chemotherapy in clinically disseminated breast cancer is to palliate symptoms and to improve the quality of life. Using conventional chemotherapy regimens in metastatic breast cancer, response rates of 50% to 60% are commonly achieved (Jones et al, 1994) . Combination chemotherapy has also been shown to prolong the survival of these patients from first recurrence, although there has not been a significant improvement in long-term survival in the past ten years. Until more effective chemotherapeutic regimens that result in durable remissions are developed, a significant decrease in mortality rate will not be observed (Ross et al, 1985) .
A correlation between increased dose intensity and better outcome has been described in metastatic disease (Hryniuk et al, 1986) . Dose intensity could also be increased by the use of lowdose continuous infusion chemotherapy (Lokich and Anderson, 1995) . The response rate to single-agent 5-fluorouracil administered by short infusion was 26% in an overview of 1263 breast cancer patients (Carter, 1976) . 5-FU is an S-phase-specific agent with a short serum half-life of 10-20 min owing to rapid catabolism to its metabolites (Fraile et al, 1980) , supporting a rationale for continuous infusion over bolus administration. Continuous infusion 5-FU has been used in several phase II studies against solid tumours. Significant activity has been demonstrated against colorectal carcinoma and breast cancer, with response rates Received 17 February 1997 Revised 17 June 1997 4ccepted 30 October 1997 Correspondence to: J-Y Pierga ranging from 32% (Hansen et al, 1987) to 53% (Huan et al, 1989) . Doses of 300 to 350 mg m-2 day-1 for infusions lasting more than 30 days were achieved in early studies (Lokich et al, 1981) . The breast cancer studies included some patients who responded to infusional 5-FU and were previously resistant to bolus therapy (Hansen, 1991) . A recent, detailed review of infusional 5-FU in advanced breast cancer has concluded that this administration is associated with superior clinical response rates over conventional bolus therapy (Anderson, 1993) .
Using a continuous infusion of 5-FU over a twice-monthly, 5-day course (days 1-5 and 15-19) associated with 4-weekly injections of doxorubicin, cyclophosphamide and vindesine on days 2, 5, 16 and 19, we have reported previously an objective response rate of 74% with a complete response rate of 28% in a small series of 48 patients with metastatic breast carcinoma (Jouve et al, 1989) .
Median response and survival duration was 18 and 27 months respectively. In a second trial, we treated 34 not previously treated metastatic breast cancer patients and 49 patients with a previous regimen, with a combination of a continuous ambulatory venous infusion of 5-FU 350 mg m-2 day-' and oral cyclophosphamide 100 mg m2 day-over 15 days, together with a weekly administration of vincristine (0.8 mg m-2) and doxorubicin (15 mg m-2) on days 1, 8 and 15. The overall response rates were 55% in chemotherapy-naive and 42% in pretreated patients (Raymond et al, 1996) . Tolerance was better than in our previous combination. A similar regimen has been reported to give an 83% response rate in the first line of chemotherapy in advanced breast cancer patients (Gordon et al, 1990) .
The aim of the present study was to compare the efficacy of a continuous infusion of 5-fluorouracil together with weekly doxorubicin and cyclophosphamide administration with a 'classical' monthly regimen of the same drugs as the first line of chemotherapy in metastatic breast carcinoma.
PATIENTS AND METHODS Patients
Patients had to be above 18 years of age and to have histologically confirmed carcinoma of the breast, metastatic disease with lesions that could be evaluated. Patients who had received any chemotherapy for metastatic disease were excluded. Patients were ineligible if they had a granulocyte count of less than 1.5 x 109 1-1 or a platelet count of less than 100 x 109 1-1, unless myelosuppression was caused by bone marrow involvement. Patients were also excluded if they had a bilirubin level 2 1.5 times normal, a history of congestive heart failure or had brain metastases as the only evidence of tumour spread. Patients were allowed to undergo concurrent irradiation provided that they had assessable or measurable disease outside the field of irradiation.
Treatment protocol
Patients were randomly assigned to receive either FAC bolus chemotherapy or FULON infusional chemotherapy. FAC consisted of 5-fluorouracil (F), 600 mg i-2 i.v. over 1 h on days 1, 2 and 3, doxorubicin (A), 50 mg m-2 i.v. bolus on day 1 and cyclophosphamide (C) 
Evaluation procedures
Pretreatment evaluation included a complete history and physical examination, measurement of all palpable lesions, complete blood counts, liver function tests, renal function tests, measurements of serum electrolytes and calcium, chest radiograph and radionuclide bone scan. Patients with abnormal bone scans had conventional radiological examinations of areas of increased uptake. A computerized tomographic scan of the head was required for patients with neurological symptoms. The complete blood count was repeated before each course of therapy; the biochemical tests were repeated if abnormal values requiring dose modification were found before any treatment or for the evaluation of new or worsening symptoms.
A physical examination was performed before each cycle. Chest radiographs were also repeated before each cycle. All metastatic sites were re-evaluated with appropriate scanning and radiographic films at 4, 8, 12 and 18 months.
Assessment of response
A complete response (CR) was defined as the disappearance of all known metastases. A partial response (PR) was defined as a decrease of 50% or more in the product of the longest perpendicular diameters of measurable lesions. Patients with a less than 50% decrease in the size of measurable metastases (which excluded bone lesions) were considered to have stable disease (SD). Those who had more than a 25% increase in the size of any measurable lesion or in whom a new lesion developed were considered to have progressive disease (PD). Time to progression was defined as the time from randomization until disease progression or the last day of follow-up. Survival was calculated as the time from randomization until death or the last day of follow-up. Early death before response assessment was recorded as tumour progression.
Toxicity
Toxicity was assessed according to the WHO criteria (Miller et al, 1981) . The most severe toxicity grade was recorded per patient. toxicity) (Goldhirsch et al, 1989) . This questionnaire was composed of 13 items. Toxicity was considered to be present when the patient reported at least one of those 13 symptoms.
Statistical analysis
Simple random sampling was used to allocate patients to treatment, and intention-to-treat analyses were used. Differences between treatment groups were analysed by chi-square tests for categorical variables and Student's t-test for continuous variables. The survival and response duration curves were determined using a Kaplan-Meier product-limit method (Kaplan and Meier, 1958) . Statistical significance between treatment groups was assessed using the log rank test. Multivariate analysis was carried out to assess the relative influence of prognostic factors on response and overall survival, using the Cox proportional hazard model in a forward stepwise procedure (Cox, 1972) . The Breslow test was used to compare different samples subject to unequal patterns of censorship (Breslow, 1970) . 
Quality of life assessment
The quality of life assessment was based both on the Rosser and Kind (1978) index as well as on the HMQ questionnaire (Fagnani et al, 1992) . Patients received the questionnaire by mail. When patients were not judged able to answer the questions on their own, index (disability and distress) was established by the investigator. A complementary study was carried out by submitting a subgroup of patients to a toxicity-oriented self-questionnaire, according to Gelber and Goldhirsch who proposed the Q-TWiST (qualityadjusted survival analysis relative to time without symptoms and RESULTS Between January 1990 and June 1993, 258 metastatic breast cancer patients who met all the eligibility criteria were included in this study. The pretreatment characteristics of these patients in the two groups were not statistically different (Table 1) . The distribution of the metastatic sites is given in Table 2 . The objective response rate for all patients was 54%. Objective response rates according to FAC or FULON regimens were not significantly different: 54% vs 53% at 4 months and 56% vs 52% at 8 months (Table 3) . Twenty-three patients in the FAC group and 32 in the FULON group finally crossed over after 4 months of treatment. At 8 months, response rates for patients who had not crossed over were 58% and 57% in the FAC and FULON arms respectively. Median overall survival duration for all patients was 22 months, and median time to progression was 14 months. There Table 4 . Pejorative prognostic factors for survival in these patients with metastatic breast cancer were elevation of lactate dehydrogenase (LDH) levels ( Figure  2A ), increasing number of metastatic sites, absence of progesterone receptor expression, presence of liver metastasis ( Figure  2B ), a low Kamofsky index (< 60) and a history of previous adjuvant chemotherapy. For all these parameters, there was no difference in either treatment arm. Tolerance was better in the continuous infusion arm, as shown in and 71% of patients respectively (P < 0.05). This difference lost statistical significance when alopecia was excluded.
DISCUSSION
Combination chemotherapy with infusional 5-FU is able to provide a high response rate in breast cancer. A response rate of 84% in a series of 43 patients with metastatic or locally advanced breast cancer has been published. These patients had been treated with a combination of 5-FU 200 mg mi-2 day-' via an ambulatory pump for 6 months with epirubicin 50 mg in-2 i.v. and cisplatin 60 mg m-2 i.v. (ECF) every 3 weeks for eight courses (Jones et al, 1994) .
Similar results have been achieved by the same team with a combination in which carboplatin had been substituted for cisplatin (Bonnefoi et al, 1996) . The original ECF regimen was also able to provide an overall response rate of 98% with 66% complete remission in a series of 50 patients with large primary potentially operable breast cancers (Smith et al, 1995) . More recently, Gabra et al (1996) reported a response rate of 76% in locoregionally recurrent and metastatic breast cancer with a regimen of weekly doxorubicin and continuous infusional 5-fluorouracil.
A favourable overall response rate of 54% was obtained in our trial with the FULON regimen. In this trial, FULON appeared to British Journal of Cancer (1998) 77(9), 1474-1479 A be equivalent to the FAC regimen in terms of response rate and overall survival. Median overall survival duration for all patients was 22 months, and median response duration was 14 months, similar to published data on chemotherapy in metastatic breast cancer (Ross et al, 1985) .
FULON was better tolerated than FAC in terms of haematological toxicity and nausea and vomiting. Overall drug-related toxicity for all patients during either of these treatments was acceptable.
Mucositis was considerably reduced in both groups by systematic prevention with anti-fungicides. Toxicity with infusional therapy appears not to be greater than with intermittent bolus treatment, although individual toxicities may differ. Myelosuppression is reduced with infusional treatments, whereas stomatis and diarrhoea may be greater. The lack of an increase in toxicity with infusional chemotherapy is all the more impressive when one considers that the total dose per month is increased over the dose per month given with standard conventional chemotherapy (Smith et al, 1995) . There was no significant difference in terms of quality of life between the FAC and FULON treatments.
Factors associated with poor response rates and decreased overall survival in our study were increased LDH levels, the number of involved sites, progesterone receptor negativity, liver involvement, poor performance status and previous adjuvant chemotherapy. Extent of disease and poor performance status are classically associated with poor survival in metastatic breast cancer (Hortobagyi et al, 1983 ). An association between previous adjuvant treatment and poor response to treatment on relapse was first suggested in 1981 (Chlebowski et al, 1981) . More recent studies have confirmed this observation (Bonneterre and Mercier, 1993; Houston et al, 1993; Rubens, 1993) . LDH level is not a usual prognostic factor described in the literature for metastatic breast cancer, but this parameter has a very strong correlation with poor survival in our series. For all of these parameters, there was no significant difference when adjusted for chemotherapy modality group. Although anthracyclines are the most active single agents in patients with breast cancer, toxicity can be severe in patients with impaired liver function and reduced hepatic clearance (Benjamin et al, 1974) . In patients with a poor performance status or low bone marrow reserve, massive liver involvement or lymphangitic pulmonary metastases, weekly administration of 15-20 mg m-2 doxorubicin is associated with fewer complications without a reduction in its effectiveness compared with the conventional dose of 50-75 mg m-2 every 3 weeks, as shown by Scheithauer et al (1985) . Patients with breast cancer and liver metastases who have abnormal biochemistry have been treated efficiently with weekly epirubicin 25 mg m-2, with adjustments of dose intensity for myelosuppression in 36 cases (Twelves et al, 1989) . Elimination of anthracyclines may be delayed in patients with liver dysfunction, increasing the dose intensity of doxorubicin in a weekly regimen such as FULON without an increase in toxicity.
Nevertheless, a low weekly dose of doxorubicin might be less effective than a higher monthly dose, as reported in the randomized trial of Blomqvist et al (1992) . In this study, 174 patients with metastatic breast cancer previously untreated with anthracycline cytotoxic agents were randomized into one group receiving FEC (5-fluorouracil, 500 mg m-2, epirubicin, 60 mg m-2 and cyclophosphamide, 500 mg m-2) once every 4 weeks and another group receiving the treatment once a week in the same monthly dosage. Monthly FEC gave significantly higher response rates than weekly treatments (52% vs 34%, P = 0.01). Time to progression and overall survival were significantly longer with monthly FEC. Haematological toxicity was significantly more severe in the monthly group, as was nausea and vomiting. Both efficacy and toxicity increased when the treatment was given once a month compared with the weekly schedule.
One explanation of the lower efficiency of the weekly regimen could be the early induction of MDRJ gene expression or the selection of primary resistant cells by repeated low doses of anthracycline as shown in vitro. Early expression of MDRJ has been demonstrated recently in a neoadjuvant regimen for breast cancer, appearing during the first month of treatment. This expression was correlated with response to chemotherapy (Chevillard et al, 1996) . Another point is that the theoretical total dose of doxorubicin was 10% lower in the FULON regimen compared with the FAC regimen. Dose intensity of delivered doxorubicin has not been assessed in this study.
We conclude that the two regimens, FAC and FULON, seem to be equally effective as a first line of chemotherapy in metastatic breast cancer. Toxicity of the FULON regimen seems to be lower.
Continuous infusion vs bolus infusion of 5-FU cannot be compared, as the administration of doxorubicin and cyclophosphamide varies between the two regimens. In the FULON arm, the efficiency of continuous infusion of 5-FU could have been lowered by a weekly instead of a monthly delivery of doxorubicin and cyclophosphamide. The continuous infusion of 5-FU associated with monthly classical delivery of doxorubicin and cyclophosphamide should be investigated further.
